UNSPSC 51433805: Mopidralazine

This classification denotes an antihypertensive agent with the molecular formula C14H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96600S6GLK, chemically known as 4-(6-((2,5-dimethylpyrrol-1-yl)amino)-3-pyridazinyl)morpholine but generally known as mopidralazine, which bears US NIH Compound Identifier 71143. European Medicines Agency schedules Mopidralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09059MIG.

UNSPSC 51433805 Mopidralazine, a Commodity code, represents medications procured by state and local governments for emergency medical services, pharmacy benefit programs, and health systems. The code encompasses individual pharmaceutical products supplied through direct-purchase agreements with manufacturers or wholesalers. State and local buyers under this code include fire departments (through municipal purchasing departments), state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. Work solicited ranges from small-volume emergency medications for emergency medical services to large multi-state pharmaceutical supply contracts with detailed product specifications, pricing models, and compliance requirements including cGMP certification, Drug Supply Chain Security Act compliance, and FDA safety standards.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026, estimated contract value $40,000.00) to supply labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with a Small Local Business Enterprise sheltered-market set-aside offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) serving Minnesota and Oregon, requiring vendors to distribute through three specified wholesalers and meet detailed pricing and compliance criteria. Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling early-stage state exploration of alternative procurement models outside traditional pharmacy benefit manager relationships.